Egyptian HAE patients to be studied for better care insights
NCT ID NCT07218393
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will collect information from medical records and routine clinic visits of 100 people in Egypt with hereditary angioedema (HAE) type I or II. The goal is to understand how the condition is diagnosed and managed in current medical practice. No new treatments are being tested; it is purely an observational study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA (HAE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ain shams university hospital
Cairo, 11535, Egypt
-
Ain shams university hospital_Pediatrics
Cairo, 11535, Egypt
-
Alexandria university_Clinical Research Center
Alexandria, 21526, Egypt
-
Cairo university hospital
Giza, 11632, Egypt
-
Cairo university hospital_Pediatrics
Giza, 11632, Egypt
-
Mansoura university hospital
Al Mansurah, 35511, Egypt
-
Zagazig university hospital
Zagazig, 44511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple pill shield HAE patients from Procedure-Triggered attacks?
- Teens with rare swelling disorder get new drug tested
- New daily pill aims to stop HAE attacks, but trial cut short
- New drug navenibart aims to tame hereditary swelling attacks
- HAE patients and caregivers speak out: the hidden costs of On-Demand treatment
- Real-world study shows lanadelumab keeps HAE attacks at bay for many patients